Open Access Open Access  Restricted Access Subscription Access

An Indispensible Parameters of Glycogen Storage Disease Include Objectives, Classification, Etiology, Patho Physiology, Diagnosis, Differential Diagnosis, Treatment and Prognosis

Muralinath E., Radhakrishna P., Guruprasad M., Madhavi Latha C., Srinivas M., Ramesh Bhumaiyya S., Ugander Reddy, Mallesh P., Pallavi M., Venkatesh D., Kishan Rao M.

Abstract


Glycogen storage diseases (GSDs), also termed as glycogenoses, are inherited inborn errors of carbohydrate metabolism. GSDs may be characterized at any age, from neonatal life to adulthood. These diseases normally happen because of a lack of specific enzymes that participated in the breakdown of glycogen and lead to the abnormal buildup of glycogen in the liver or skeletal muscles. Affected patients have hypoglycemia, exercise-induced weakness, and potential long-term problems due to the inability to mobilize glucose from glycogen.

Clinical assessment, biochemical tests (such as blood glucose and liver enzyme levels), and genetic identification of mutations in certain enzymes are used to assess GSDs. Assessing organ involvement may also be aided by imaging tests. Treating the underlying enzyme deficit and preventing complications are the main goals of management.

Treatment frequently includes dietary modifications like frequent feedings of complex carbohydrates, controlling blood glucose levels and obstruct hypoglycemia. In some cases, enzyme replacement therapy or liver transplantation may be specified. No cure is currently available for this group of metabolic disorders.

The prognosis varies, depending on the specific GSD type, along with some forms related to a relatively normal life expectancy, while others may result in severe complications such as organ failure as well as developmental delays. Early diagnosis and appropriate management may promote outcomes in a significant manner.

The goal of this exercise for medical professionals is to increase students' competence in GSD diagnosis and treatment. Participants will learn more about pathogenesis, clinical presentation, and epidemiology of illness. The best evaluation and management practices of GSDs will also be discussed. This educational activity will equip healthcare professionals to collaborate in an effective manner within an interprofessional team caring for patients along with this subset of rare diseases.

 


Full Text:

PDF

References


Hicks, J., Wartchow, E., & Mierau, G. (2011). Glycogen storage diseases: A brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastructural Pathology, 35(5), 183–196.

Özen, H. (2007). Glycogen storage diseases: New perspectives. World Journal of Gastroenterology, 13(18), 2541–2553.

Kanungo, S., Wells, K., Tribett, T., & El-Gharbawy, A. (2018). Glycogen metabolism and glycogen storage disorders. Annals of Translational Medicine, 6(24), 474.

Kannourakis, G. (2002). Glycogen storage disease. Seminars in Hematology, 39(2), 103–106.

Parikh, N. S., & Ahlawat, R. (2023, August 8). Glycogen storage disease type I. In StatPearls. StatPearls Publishing.

Schreuder, A. B., Rossi, A., Grünert, S. C., & Derks, T. G. J. (2010, March 9). Glycogen storage disease type III. In M. P. Adam et al. (Eds.), GeneReviews®. University of Washington, Seattle.

Chan, J., Desai, A. K., Kazi, Z. B., Corey, K., Austin, S., Hobson-Webb, L. D., Case, L. E., Jones, H. N., & Kishnani, P. S. (2017). The emerging phenotype of late-onset Pompe disease: A systematic literature review. Molecular Genetics and Metabolism, 120(3), 163–172.

Applegarth, D. A., Toone, J. R., & Lowry, R. B. (2000). Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics, 105(1), e10.

Ockerman, P. A. (1965). Glycogen storage disease in Sweden. Acta Paediatrica Scandinavica, 87(Suppl. 160), 1–31.

Tarnopolsky, M. A. (2016). Metabolic myopathies. Continuum (Minneapolis, Minnesota), 22(6), 1829–1851.

Oldfors, A., & DiMauro, S. (2013). New insights in the field of muscle glycogenoses. Current Opinion in Neurology, 26(5), 544–553.

Hijazi, G., Paschall, A., Young, S. P., Smith, B., Case, L. E., Boggs, T., Amarasekara, S., Austin, S. L., Pendyal, S., El-Gharbawy, A., Deak, K. L., Muir, A. J., & Kishnani, P. S. (2021). A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III. Molecular Genetics and Metabolism Reports, 29, 100821.

Morris, A. A., Thekekara, A., Wilks, Z., Clayton, P. T., Leonard, J. V., & Aynsley-Green, A. (1996). Evaluation of fasts for investigating hypoglycaemia or suspected metabolic disease. Archives of Disease in Childhood, 75(2), 115–119.

Weinstein, D. A., Steuerwald, U., De Souza, C. F. M., & Derks, T. G. J. (2018). Inborn errors of metabolism with hypoglycemia: Glycogen storage diseases and inherited disorders of gluconeogenesis. Pediatric Clinics of North America, 65(2), 247–265.

Orho, M., Bosshard, N. U., Buist, N. R., Gitzelmann, R., Aynsley-Green, A., Blümel, P., Gannon, M. C., Nuttall, F. Q., & Groop, L. C. (1998). Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. The Journal of Clinical Investigation, 102(3), 507–515.

Coleman, R. A., Winter, H. S., Wolf, B., & Chen, Y. T. (1992). Glycogen debranching enzyme deficiency: Long-term study of serum enzyme activities and clinical features. Journal of Inherited Metabolic Disease, 15(6), 869–881.

Kohler, L., Puertollano, R., & Raben, N. (2018). Pompe disease: From basic science to therapy. Neurotherapeutics, 15(4), 928–942.

Bartram, C., Edwards, R. H., & Beynon, R. J. (1995). McArdle’s disease—Muscle glycogen phosphorylase deficiency. Biochimica et Biophysica Acta, 1272(1), 1–13.

Lefeuvre, C., Schaeffer, S., Carlier, R. Y., Fournier, M., Chapon, F., Biancalana, V., Nicolas, G., Malfatti, E., & Laforêt, P. (2020). Glycogenin-1 deficiency mimicking limb-girdle muscular dystrophy. Molecular Genetics and Metabolism Reports, 24, 100597.

Molares-Vila, A., Corbalán-Rivas, A., Carnero-Gregorio, M., González-Cespón, J. L., & Rodríguez-Cerdeira, C. (2021). Biomarkers in glycogen storage diseases: An update. International Journal of Molecular Sciences, 22(9), Article 474).

Saltik-Temizel, I. N., Coşkun, T., Yüce, A., & Koçak, N. (2005). Fanconi–Bickel syndrome in three Turkish patients with different homozygous mutations. Turkish Journal of Pediatrics, 47(2), 167–169.

Ferreira, C. R., & Gahl, W. A. (2017). Lysosomal storage diseases. Translational Science of Rare Diseases, 2(1–2), 1–71.

Whitehouse, F. W., & Bryan, H. G. (1959). Glucagon for treatment of insulin hypoglycemia: Its use in the patient with diabetes. American Practitioner and Digest of Treatment, 10, 1326–1330.

Martin, A. P., Bartels, M., Schreiber, S., Buehrdel, P., Hauss, J., & Fangmann, J. (2006). Successful staged kidney and liver transplantation for glycogen storage disease type Ib: A case report. Transplantation Proceedings, 38(10), 3615–3619.

Valenzuela, P. L., Santalla, A., Alejo, L. B., Merlo, A., Bustos, A., Castellote-Bellés, L., Ferrer-Costa, R., Maffiuletti, N. A., Barranco-Gil, D., Pinós, T., & Lucia, A. (2024). Dose–response effect of pre-exercise carbohydrates under muscle glycogen unavailability: Insights from McArdle disease. Journal of Sport and Health Science, 13(3), 398–408.


Refbacks

  • There are currently no refbacks.